News

Once prostate cancer no longer responds to hormonal therapy, the cancer is called castration-resistant. Find out which ...
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update ...
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across ...